Skip to main content
NCBI home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1975 Dec;81(3):669–682.

The relation of infection with the hepatitis B agent to primary hepatic carcinoma.

B S Blumberg, B Larouzé, W T London, B Werner, J E Hesser, I Millman, G Saimot, M Payet
PMCID: PMC2032339  PMID: 174434

Abstract

In Asia, Africa, and other tropical areas, primary hepatic carcinoma (PHC) is associated with liver cirrhosis of the postnecrotic (macronodular) type. Chronic viral hepatitis is likely to be the cause of this cirrhosis in many patients from regions where chronic infection with the hepatitis B virus (HBV) is common. More than 95% of patients with hepatoma (in Mali and Senegal) have evidence of infection with HBV, a much higher frequency than in controls. Thirty-nine of 62 patients with PHC had hepatitis B surface antigen (HBsAg) (controls, 8 of 98) and 56 of 63 (controls, 26 of 100) had antibody against hepatitis B core antigen (anti-HBc). In earlier studies, we demonstrated a maternal effect of HBsAg. If the mother has the antigen and the father does not, the children are much more likely to also have HBsAg than if the father has the antigen and the mother does not (93/161 = 57.8% when mother is positive vs. 28/135 = 20.7% when father is positive; P = 0.6 X 10(-10)). Studies in Greece and in the Solomon Islands show that presence of HBsAg in parents affects the sex ratio of the offspring of the mating. This implies that the presence of the agent in a parent can affect the fetus early in life. Parental studies in the west African hepatoma patients showed that there is a very high frequency of HBsAg in mothers (71.6%), while the frequency in fathers (18.5%) is significantly less. This suggests that the development of hepatoma in offspring is related to infection in parents. Several years ago, we described a vaccine which may be useful in preventing infection with hepatitis B. Strategies are discussed which might be effective in preventing the development of carriers with, it is hoped, a consequent decrease in the frequency of HBV carriers, chronic hepatitis, and primary hepatic carcinoma. The strategy would employ methods for decreasing the frequency of the agent in the environment by the application of public health methods including the vaccination of appropriate newborns and other members of the population.

Full text

PDF
669

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blumberg B. S., Gerstley B. J., Hungerford D. A., London W. T., Sutnick A. I. A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis. Ann Intern Med. 1967 May;66(5):924–931. doi: 10.7326/0003-4819-66-5-924. [DOI] [PubMed] [Google Scholar]
  2. Economidou I., Hadziyannis S., Paraskevas E., Binopoulou A., Hesser J. E., Lustbader E., Blumberg B. S. Australia antigen (HBsAg) carriers in a Greek community. Studies of transaminase (SGPT) levels. Res Commun Chem Pathol Pharmacol. 1975 Apr;10(4):703–713. [PubMed] [Google Scholar]
  3. Economidou I., Hadziyannis S., Paraskevas E., Binopoulou A., Hesser J. E., Lustbader E., Blumberg B. S. Australia antigen (HBsAg) carriers in a Greek community. Studies of transaminase (SGPT) levels. Res Commun Chem Pathol Pharmacol. 1975 Apr;10(4):703–713. [PubMed] [Google Scholar]
  4. Kohler P. F., Dubois R. S., Merrill D. A., Bowes W. A. Prevention of chronic neonatal hepatitis B virus infection with antibody to the hepatitis B surface antigen. N Engl J Med. 1974 Dec 26;291(26):1378–1380. doi: 10.1056/NEJM197412262912603. [DOI] [PubMed] [Google Scholar]
  5. Kukowski K., London W. T., Sutnick A. I., Kahn M., Blumberg B. S. Comparison of progeny of mothers with and without Australia antigen. Hum Biol. 1972 Sep;44(3):489–499. [PubMed] [Google Scholar]
  6. Maugh T. H., 2nd Hepatitis B: a new vaccine ready for human testing. Science. 1975 Apr 11;188(4184):137–138. doi: 10.1126/science.188.4184.137. [DOI] [PubMed] [Google Scholar]
  7. Maupas P., Werner B., Larouzé B., Millman I., London W. T., O'Connell A., Blumberg B. S. Antibody to hepatitis-B core antigen in patients with primary hepatic carcinoma. Lancet. 1975 Jul 5;2(7923):9–11. doi: 10.1016/s0140-6736(75)92951-7. [DOI] [PubMed] [Google Scholar]
  8. Mazzur S., Blumberg B. S., Friedlaender J. S. Silent maternal transmission of Australia antigen. Nature. 1974 Jan 4;247(5435):41–43. doi: 10.1038/247041a0. [DOI] [PubMed] [Google Scholar]
  9. Obayashi A., Okochi K., Mayumi M. Familial clustering of asymptomatic carriers of Australia antigen and patients with chronic liver disease or primary liver cancer. Gastroenterology. 1972 Apr;62(4):618–625. [PubMed] [Google Scholar]
  10. PAYET M., CAMAIN R., PENE P. Le cancer primitif du foie; etude critique à propos de 240 cas. Rev Int Hepatol. 1956;6(1):1–86. [PubMed] [Google Scholar]
  11. STEINER P. E., DAVIES J. N. Cirrhosis and primary liver carcinoma in Uganda Africans. Br J Cancer. 1957 Dec;11(4):523–534. doi: 10.1038/bjc.1957.64. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Schweitzer I. L., Wing A., McPeak C., Spears R. L. Hepatitis and hepatitis-associated antigen in 56 mother-infant pairs. JAMA. 1972 May 22;220(8):1092–1095. [PubMed] [Google Scholar]
  13. Stevens C. E., Beasley R. P., Tsui J., Lee W. C. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med. 1975 Apr 10;292(15):771–774. doi: 10.1056/NEJM197504102921503. [DOI] [PubMed] [Google Scholar]
  14. Terés J., Guardia J., Bruguera M., Rodes J. Hepatitis-associated antigen and hepatocellular carcinoma. Lancet. 1971 Jul 24;2(7717):215–215. doi: 10.1016/s0140-6736(71)90926-3. [DOI] [PubMed] [Google Scholar]
  15. Vogel C. L., Anthony P. P., Sadikali F., Barker L. F., Peterson M. R. Hepatitis-associated antigen and antibody in hepatocellular carcinoma: results of a continuing study. J Natl Cancer Inst. 1972 Jun;48(6):1583–1588. [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES